Bristol-Meyers Squibb to Halt Sales of Serzone in U.S.
May 20, 2004
Bristol-Myers Squibb will stop selling its controversial antidepressant Serzone in the United States starting next month, a company spokesman said. Serzone has been linked to dozens of cases of liver failure and injury, including at least 20 deaths.
The drug, the subject of several lawsuits, is one of 17 to be discontinued due to poor sales and growing competition, said Robert Hutchinson, a spokesman for Bristol-Myers.